NRX Pharmaceuticals, Inc. 8-K

What Happened

• NRX Pharmaceuticals, Inc. (NRXP) filed an 8-K on March 24, 2026 reporting results from its 2025 Annual Meeting. Shareholders elected Chaim Hurvitz and Michael Taylor as Class I directors (terms to the 2028 annual meeting) and approved Amendment No. 1 to the company’s 2021 Omnibus Incentive Plan. The amendment became effective upon stockholder approval and increases the plan’s annual “evergreen” share reserve.

Key Details

• Amendment No. 1 increases the annual automatic share increase from the prior measure (the lesser of 1% of outstanding shares or board-determined amount) to the lesser of: (a) 3,187,234 shares, (b) 5% of outstanding shares (fully diluted), or (c) a number determined by the board. A copy of the amendment is filed as Exhibit 10.1.
• Director election results: Chaim Hurvitz — For 9,858,733; Withheld 841,471; Broker non-vote 7,157,034. Michael Taylor — For 9,889,210; Withheld 810,994; Broker non-vote 7,157,034.
• Omnibus Incentive Plan amendment vote: For 5,976,632; Against 4,484,064; Abstain 239,508; Broker non-vote 7,157,034.
• Other votes: Ratification of Weinberg & Company, P.A. as auditor — For 17,351,069; Against 256,023; Abstain 250,146. Advisory approval of executive compensation (say-on-pay) — For 9,969,575; Against 415,739; Abstain 314,890; Broker non-vote 7,157,034.

Why It Matters

• The approved amendment increases the pool of shares available for equity awards, which can support hiring and retention through stock-based compensation but may also lead to additional share dilution for current shareholders.
• The election of two Class I directors and ratification of the auditor are governance outcomes investors watch for board composition and oversight continuity.
• The non-binding advisory vote in favor of executive compensation indicates shareholder support for current pay practices, but it is advisory and not binding on the board.